卡非佐米联合地塞米松诱导序贯来那度胺、克拉霉素和地塞米松巩固及来那度胺维持治疗新诊断多发性骨髓瘤
这项2期研究评估了Car-BiRd序贯方案(Kd诱导至最大反应,BiRd巩固至下一最大反应,后来那度胺维持)在新诊断多发性骨髓瘤患者中的安全性和有效性。中位PFS为37.3个月(95% CI 27.9-52.7),中位随访60个月时中位OS未达到,毒性主要为低级别且可管理。
要点
- Car-BiRd序贯方案总缓解率94%,≥VGPR率83%,CR/sCR率35%,未达55%的CR目标。
- 中位PFS 37.3个月(95% CI 27.9-52.7),中位随访60个月OS未达到。
- 血液学毒性低于PI/IMiD联合方案预期,毒性以低级别为主。
核心结论
- Car-BiRd序贯方案对新诊断多发性骨髓瘤有效且安全,包括不适合移植的患者。
- 该方案未达到研究设定的CR率55%的目标终点。
研究设计与样本
- 2期研究,评估Car-BiRd方案:卡非佐米和地塞米松诱导至最大反应,来那度胺、克拉霉素和地塞米松巩固至下一最大反应,后来那度胺维持。
主要发现
- 总缓解率94%,83%患者达到≥VGPR,35%达到CR/sCR。
- CR/sCR率从Kd诱导的7%增至BiRd巩固的21%和来那度胺维持的35%。
- 中位PFS为37.3个月(95% CI 27.9-52.7),中位随访60个月时中位OS未达到。
- 毒性主要为低级别且可管理,血液学毒性低于PI/IMiD联合方案预期。
关键数值与推荐
- 总缓解率94%,≥VGPR率83%,CR/sCR率35%。
- CR/sCR率:Kd诱导7%,BiRd巩固21%,来那度胺维持35%。
- 中位PFS 37.3个月(95% CI 27.9-52.7),中位OS未达到(随访60个月)。
临床怎么用
- Car-BiRd序贯方案可作为新诊断多发性骨髓瘤的初始治疗选择,包括不适合移植者。
- 该方案毒性较低,尤其血液学毒性低于PI/IMiD联合方案预期。
局限性
- 研究为2期单臂设计,未达到预设CR率55%的目标终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combination treatment regimens including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and a corticosteroid are standards of care for initial treatment of multiple myeloma (MM). We aimed to evaluate if a sequential treatment program using PI induction followed by IMiD based consolidation and maintenance could achieve similar outcomes with reduced toxicities. This phase 2 study was designed to assess the safety and efficacy of the Car-BiRd regimen: carfilzomib and dexamethasone (Kd) induction until maximum response, followed by lenalidomide, clarithromycin and dexamethasone (BiRd) consolidation until next maximum response, then lenalidomide maintenance in patients with newly diagnosed MM. Seventy-two patients, including both transplant eligible and ineligible patients, were enrolled and evaluated for response. The overall response rate to the Car-BiRd regimen was 94% with 83% of patients achieving a ≥ VGPR and 35% achieving a CR/sCR. The rate of CR/sCR increased from 7% with Kd induction to 21% with BiRd consolidation and 35% with lenalidomide maintenance. These results did not meet the study's target endpoint of a CR rate of 55%. The median PFS using this deferred transplant approach was 37.3 months (95% CI 27.9, 52.7) and median OS was not reached with a median follow-up of 60 months. Toxicities were primarily low grade and manageable. Hematologic toxicities were lower than those expected with a combination PI/IMiD protocol. The sequential Car-BiRd regimen is an effective and safe approach for the upfront treatment of MM including patients unfit for transplant.
引用
- Forsberg PA, Rossi AC, Boyer A, et al. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. Am J Hematol. 2021. PMID: 34424561. doi:10.1002/ajh.26329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。